30DEC

Libyan International Conference for Health Sciences

The First Libyan International Conference for Health Sciences (2024): Open University, Tripoli, Libya
Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
https://app.periodikos.com.br/journal/medjpps/article/doi/10.5281/zenodo.14645885

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

review

A comprehensive analysis of disclosed synthetic strategies in prior arts from 1970-2012 (Part I) regarding synthesizing the renowned drug, Febuxostat, and its related compounds

Sanjay Sukumar Saralaya

http://dx.doi.org/10.5281/zenodo.14645885 Mediterr J Pharm Pharm Sci, Ahead of Print, 2025
PDF
PDF
Downloads: 0
Views: 30

Abstract

Febuxostat Fb, a nonpurine selective inhibitor of oxidized and reduced forms of xanthine oxidase. It was approved by the FDA in 2008 (EU) & 2009 (US) for the management of hyperuricemia in patients with gout. This review article provides the exhaustive and systematic review coverage of prior art disclosures on the synthesis of Febuxostat Fb and its related compounds from 1970-2012. In line with this, the prior arts were sourced from various common and renowned search tools like Google Scholar and Google Patents using different search terms/sentences. Additionally, back and cross reference sourcing initiatives had assisted in gathering the complete past scientific disclosures on Fb. During the process, 67 publications (as research articles and filed patents) were collected and the reaction schemes that are specific to each work were elaborated for the better readability of budding researchers. In this article, every disclosure has been given priority from 1970-2012 and hence 41 reaction schemes were framed in a yearly chronology. Meanwhile, the country-wise details of research organizations/institutions/laboratories were included where the disclosed work was executed. This article would certainly assist the researchers in understanding the past developments on the synthesis of Fb and its closely related compounds.

Keywords

Benzothioamides, Febuxostat, phenylthiazoles, raw material, synthesis

References

  1. Becker MA, Schumacher HR, Jr Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England Journal of Medicine. 353 (23): 2450-2461. doi: 10.1056/nejmoa050373
  2. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febuxostat for treating chronic gout. Cochrane Database of Systematic Reviews. 11 (11): CD008653. doi: 10.1002/14651858. CD008653.pub2
  3. Brick N (2013) Febuxostat for treating chronic gout. International Journal of Evidence-Based Healthcare. 11 (3): 202-203. doi: 10.1111/1744-1609.12033
  4. Hainer BL, Matheson E, Wilkes RT (2014) Diagnosis, treatment, and prevention of gout. American Family Physician. 90 (12): 831-836. PMID: 25591183.
  5. Sun R, Lu J, Li H, Cheng X, Xin Y, Li C (2020) Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial. Joint Bone Spine. 87 (5): 461-466. doi. 10.1016/ j.jbspin.2020.03.017
  6. Pawar PG, Darekar AB, Saudagar RB (2019) Formulation, development and evaluation of febuxostat loaded microsponges. International Journal of Research in Advent Technology. 7 (5): 523-533. doi: 10.32622/ijrat.752019326
  7. Kaur M, Mittal A, Gulati M, Sharma D, Kumar R (2020) Formulation and in vitro evaluation of fast dissolving tablets of Febuxostat using co-processed excipients. Recent Patents on Drug Delivery and Formulation. 14 (1): 48-62. doi: 10.2174/1872211314666191224121044
  8. Bernard M (1970) Thazolylphenyl phosphates. US3518279. United States.
  9. Mikhail MG (1972) Preparation of thioamides. US3700664A. United States.
  10. Hasegawa M, Komoriya K (1994) Cyano compound and its production. JPH06345724A. Japan.
  11. Shiro K, Hisachi F, Masaichi H, Masahiro T, Ikuo N, Yoshio O, Keiji K, Hisao Y (1997) 2-arylthazole dervatives and pharmaceutical composition thereof. US5614520. United States.
  12. Hasegawa M (1998) A facile one-pot synthesis of 4-alkoxy-1,3-benzenedicarbonitrile. Heterocycles. 47 (2): 857-864. doi: 10.3987/com-97-s(n)89
  13. Watanabe K, Tanaka T, Kondo S, Fujii T (1998) Production of 2-(4-alkoxy-3-cyanophenyl)thiazole derivative and new production intermediate there for. JPH2834971B1. Japan.
  14. Minojima T, Hiramatsu T (1998) Production of 2-(3-cyanophenyl)thiazole derivative. JPH10139770A. Japan.
  15. Torii S, Minojima T (1999) Production of 2,3-dihydrobenzo(b)furan derivative and medicine. JPH11100376A. Japan
  16. Tanabe M, Minojima T, Matsumoto K (1999) Production of thiobenzamide derivative. JPH1160552A. Japan.
  17. Matsumoto K, Watanabe K, Hiramatsu T (2000) Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation. CN1275126A. China.
  18. Koichi M, Kenzo W, Toshiyuki H, Mitsutaka K (2001) Polymorphs of 2-(3-cyano-4 isobutyloxyphenyl)-4-methyl-5 thiazolecarboxylic acid and method of producing the same. US6225474B1. United States.
  19. Watanabe K, Yarino T, Hiramatsu T (2001) Production of 2-(4-alkoxy-3-cyanophenyl)thiazole derivative. JPH3202607 B2. Japan.
  20. Robbins T, Zhu H, Shao J (2005) Substituted thiazoles. WO2005012273A2. WIPO (PCT).
  21. Qiang S, Xiaomei W, Zhefeng W, Huilin S (2008) 2-(3-Cyano-4-isobuoxy phenyl)4-methyl-5-thiazole aminic acid crystal and preparation method thereof. CN101139325A. China.
  22. Qiang S, Xiaomei W, Zhefeng W, Huilin S, Weihong S, Yongchu B (2009) Crystal form and preparation of febuxostat. CN101412700A. China.
  23. Wang S, Chen J, Xue M (2009) Method for synthesizing 2-(3-cyano-4- isobutoxy phenyl)-4-methyl-carboxylate. CN101497589A. China. 
  24. Canivet J, Yamaguchi J, Ban I, Itami K (2009) Nickel-catalyzed biaryl coupling of heteroarenes and aryl halides/triflates. Organic Letters. 11 (8): 1733-1736. doi: 10.1021/ol9001587
  25. Sui Q, Wang X, Wang Z, Shi H, Wang X, Sun W (2009) Preparation of 2-(3-carboxaldehyde-4-hydroxy phenyl)-4-methyl-5-thiazole ethyl formate. CN101412699A. China.
  26. Wang D, Tang C, Mi S, Li X, Liu H, Ouyang P (2009) Method for preparing 2-(4-hydroxyl phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid ethyl ester by one pot method. CN101391988A. China.
  27. Deng F, Zhang J (2009) Febuxostat novel crystal and preparation method thereof. CN101386605A. China.
  28. Castaldi G, Rasparini M, Sillani L (2010) A process for the preparation of febuxostat. WO2010142653A1. WIPO (PCT).
  29. Jian F, Shen W (2010) Preparation method of important intermediate of novel febuxostat. CN101759657A. China.
  30. Qi W, Wang W, Yan Q, Yang Y (2010) Method for preparing febuxostat intermediate. CN101723915A. China.
  31. Zhu X, Jiang X, Zhang Y, Yin Z, Liu R, Zhou M, Shi C (2010) Preparation method of febuxostat intermediate. CN101665471A. China.
  32. Shi X, Wang S (2010) Synthesis method of 2-(3-cyan-4-isobutoxy) phenyl-4-methyl-5-thiazole formic acid. CN101863854A. China.
  33. Zhu X, Huang J, Wang Y, Wu B, Yin Z, Liu R (2010) Uloric crystal and preparation method thereof. CN101671314A. China.
  34. Liu M, Lu H, Wu J, Zhou H (2010) New crystal form Q of febuxostat and preparation method thereof. CN101824005A. China.
  35. Liu M, Lu H, Wu J, Zhou H (2010) New crystal form P of febuxostat and preparation method thereof. CN101824006A. China.
  36. Deng J, Fan B, Luo J, Tan, X, Ye W, Zhou X (2010) Febuxostat new crystal forms and preparation method thereof. CN101759656A. China.
  37. Chao J, Liu F, Liu Y, Shao L, Tong W (2010) Preparation method of new crystal form K of 2-(3-cyano-4-isobutoxy)-4-methyl-5-thiazole formic acid and other crystal forms. CN101817801A. China.
  38. He G, Li F, Wu Q, Liu W (2010) New crystal form of febuxostat and preparation method thereof. CN101671315A. China.
  39. Luo J, Jiao H, Xi W, Wang X (2010) New febuxostat crystal form and preparing method thereof. CN101684107A. China.
  40. Li Y, Zhao M, Ji C, Zhu S, Lu D, Chen Y, Hu J (2010) Method for preparing 2-(3-formacyl-4-isobutoxyphenyl)-4-methyl-1,3 thiazole-5-carboxylic acid ethyl ester. CN101921243A. China.
  41. Baumann M, Baxendale IR, Ley SV, Nikbin N (2011) An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals. Beilstein Journal of Organic Chemistry. 7: 442-495. doi: 10.3762/bjoc.7.57
  42. Birari DR, Rao DR, Kanka, RN (2011) Processes for the preparation of febuxostat and salts thereof. WO2011073617A1. WIPO (PCT).
  43. Yamamoto T, Muto K, Komiyama M, Canivet J, Yamaguchi J, Itami K (2011) Nickel-catalyzed C-H arylation of azoles with haloarenes: scope, mechanism, and applications to the synthesis of bioactive molecules. Chemistry (Weinheim an Der Bergstrasse, Germany). 17 (36): 10113-10122. doi: 10.1002/ chem.201101091
  44. Yan Q, Qi W, Yang Y, Wang W (2011) Method for preparing febuxostat intermediate. CN102002017A. China.
  45. Zhao L, Wang J, Cao J (2011) Improvement method for synthesizing febuxostat. CN102002016A. China.
  46. Zhou H, Yan M, Wang Y, Huang W, Li S, Huang X, Ren S (2011) Method for preparing febuxostat intermediate. CN102234253A. China.
  47. Zhou X, Tang X, Ye W, Luo J, Deng J (2011) Preparation method of intermediate of febuxostat. WO2011066803A1. WIPO (PCT).
  48. Zhou X, Tang X, Shi R, Ye W, Luo J, Deng J, Fan B (2011) High-purity febuxostat and the method for preparation. US20110282069A1. United States.
  49. Zheng J, Liu S, Zhang J, Cui M, Li J, Li H, Zhou H, Niu H (2011) Method for preparing febuxostat crystal A. CN102267957A. China.
  50. Anonymous (2011) Febuxostat crystal form and industrial preparation method thereof. CN102127033A. China.
  51. Zhou X, Fan B, Deng J, Tang X, Luo J, Zhang D, Ye W (2011) Novel febuxostat crystal form and its preparation method. CN1970547B. China.
  52. Thaimattam R, Dash PK, Prasad R, Dhar S (2011) Polymorphic forms of febuxostat. WO2011080651A2. WIPO (PCT).
  53. Satyanarayana RM, Venkata PRG, Prasad G (2011) Process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts. WO2011141933A2. WIPO (PCT).
  54. Zou Q (2011) Preparation method for Febuxostat intermediate. CN102229581A. China.
  55. Hong J, Li J (2011) Method for synthesizing febuxostat. CN102285937A. China.

 

  1. Wu Y, Li G, Huang J, Zhang W, Yu H, Dan Y, Fu L, Chen Y, Zhang B (2011) Method for synthesizing 2-(3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazole formic acid. CN102079731A. China.
  2. Zou Z (2011) Method for preparing 2-(3-cyano-4-isobutyl methoxyphenyl)-4-methylthiazol-5-ethyl formate. CN102070559A. China.
  3. You S, Li Y (2011) Deuterated cyanophenyl thiazoles derivative for treating gout and hyperuricemia. CN102010384A. China.
  4. Hayashisaka T, Iida Y (2011) Method for producing thiobenzamide compounds. JPH4711494B2. Japan.
  5. He X, Du L, Zhu J, Wang Y (2011) Preparation method of febuxostat. CN102120733A. China.
  6. Anonymous (2011) Method for synthesizing 2-aryl nitrile thiazole derivative and intermediate thereof. CN102276550A. China.
  7. Piran M, Metsger L (2011) Crystalline forms of febuxostat. EP2398784A1. European Patent Office.
  8. Zhang J (2012) Novel febuxostat crystal form, its preparation method and application thereof. CN102731430A. China.
  9. Guo J, Ji S (2012) Preparation method of p-hydroxythiobenzamide. Chinese patent: CN102702054A.
  10. Uemura A, Nogata T, Takeyasu T (2012) Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecaboxylic acid by poor-solvent addition method. CN102471295A. China.
  11. Wu Y, Xue P, Jin J, Yuan X, Xiao F (2012) Novel febuxostat crystal form and its preparation method. CN102442971A. China.
  12. Tombari DG, Mangone CP, Garcia MB, Vecchioli A, Labriola RA (2012) A novel febuxostat crystalline form and the process for the preparation thereof. WO2012048861A1. WIPO (PCT).
  13. Luthra PK, Khan R, Salunkhe D, Nasir A (2012) An improved process for preparation of febuxostat and its polymorphic crystalline form C thereof. WO2012131590A1. WIPO (PCT).
  14. Metsger L, Gorohovsky S, Kipnis N, Yurkovski S (2012) Processes for preparing febuxostat. WO2011031409A. WIPO (PCT).
  15. Rajadhyaksha MN, Jadhav VK, Shrigadi NB, Panandikar AM (2012) Novel process for the preparation of febuxostat. WO2012073259A1. WIPO (PCT).
  16. Komiyama M, Yajima N, Kurokawa M (2012) Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst. CN102333765A. China.
  17. Kaushik P, Thaimattam R, Prasad M (2012) Febuxostat co-crystals. WO2012098501A1. WIPO (PCT).
  18. Salaet-Ferre J, Marquillas-Olondriz F (2012) Process for preparing the crystalline form a of (2- [3-cyano-4-(2-1-butoxy) phenyl]-4-methyl -5-thiazole-carboxylic acid (febuxostat). WO2012007486A1. WIPO (PCT).
  19. Satoshi S (2012) Method for producing 4-substituted benzothoamide derivative. US20120078013A1. United States.

Submitted date:
11/10/2024

Reviewed date:
12/15/2024

Accepted date:
12/22/2024

Publication date:
01/14/2025

67868f83a9539570c7130c12 medjpps Articles
Links & Downloads
2789-1895 (Electronic) 2958-3101 (Printed)
Mediterr J Pharm Pharm Sci ©2025 All rights reserved.

Mediterr J Pharm Pharm Sci

Share this page
Page Sections